BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NC410 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NC410\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06941857-10905@assetmemo.bio
DTSTAMP:20261121T005558Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NC410: Phase 2 readout est. (NCT06941857)
DESCRIPTION:NC410\, phase 2.\nStudy: NC410 and FOLFIRINOX in Combination Wi
 th Nivolumab With or Without Ipilimumab in Patients With Untreated Metasta
 tic Pancreatic Cancer\nEstimated primary completion: December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nc410#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06941857
URL:https://assetmemo.bio/drug/nc410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
